1. Market Research
  2. > Life Sciences Market Trends
Anti-Rheumatics Market by Drug Class, Type : Global Opportunity Analysis and Industry Forecast, 2019–2026

Anti-Rheumatics Market by Drug Class, Type : Global Opportunity Analysis and Industry Forecast, 2019–2026

  • January 2020
  • 202 pages
  • ID: 5869010
  • Format: PDF
  • Allied Market Research

Summary

Table of Contents

Anti-Rheumatics Market by Drug Class (Disease Modifying Anti-Rheumatic Drugs (DMARD’s), Nonsteroidal Anti-Inflammatory Drugs (NSAID’s), Corticosteroids, Uric Acid Drugs, and Others), Type (Prescription-Based Drugs and Over-the-Counter Drugs): Global Opportunity Analysis and Industry Forecast, 2019–2026

The global anti-rheumatics market accounted for $57,229 million in 2018 and is expected to reach $71,934 million by 2026, registering a CAGR of 2.9% from 2019 to 2026.
Rheumatoid arthritis (RA) is a chronic auto-immune disorder that majorly affects joints along with articular tissues and extra-articular organs. Furthermore, this medical condition is often progressive and results in pain, stiffness, and swelling of joints. Moreover, there is no permanent cure for RA, the goals of the treatment are to reduce pain, decrease inflammation, prevent bone deformity, and improve a person’s overall function. This is achieved through pain medication, steroids, and NSAIDs that are frequently used to help with the symptoms. In addition, disease-modifying anti-rheumatic drugs (DMARDs) are used to slow down the progression of this disease. These drugs are the primary treatment for RA and have been found to improve symptoms, decrease joint damage, and improve overall functional abilities. However, early diagnosis and early treatment is the key for better management of the disease. Recent advancements with biosimilars, which may be used to treat RA and increase in approvals of the same by regulatory authorities have opened new avenues for the anti-rheumatics market.
The major factors that fuel the growth of the global rheumatoid arthritis drugs market include rise in incidence of rheumatoid arthritis and surge in geriatric population across the globe. In addition, increase in incidence of obesity worldwide is another major factor that drives the growth of anti-rheumatic market. However, side effects associated with the medication and higher cost of biologics & biosimilars restrain the growth of rheumatoid arthritis drug market. On the contrary, developments in the field of biosimilars and novel biologics are anticipated to offer profitable opportunities for the growth of the RA drugs market.
The anti-rheumatics market size is studied on the basis of drug class, type, and region to provide a detailed assessment of the market. On the basis of drug class, it is divided into disease modifying anti-rheumatic drugs (DMARD’s), nonsteroidal anti-inflammatory drugs (NSAID’s), corticosteroids, uric acid drugs, and others. By type, it is divided into prescription-based drugs and over-the-counter drugs. By region, the anti-rheumatics market size is analyzed across North America (the U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global anti-rheumatics market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments
• By Drug Class
o Disease Modifying Anti-rheumatic Drugs (DMARD’s)
o Nonsteroidal Anti-inflammatory Drugs (NSAID’s)
o Corticosteroids
o Uric Acid Drugs
o Others
• By Type
o Prescription-Based Drugs
o Over-the-Counter Drugs
• By Region
o North America
- U.S.
- Canada
- Mexico
o Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
o Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
o LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

List of key players profiled in the report:
• Pfizer, Inc.
• Johnson & Johnsons
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Celegene Corporations
• MedImmune, LLC
• Takeda Pharmaceutical Company Ltd.
• Biogen Inc.
• Celltrion Inc.
• Amgen Inc

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Sebela Pharmaceuticals
• Abbott LaboratoriesSafe In Breastfeeding

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on